+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A candidate modified-live bovine coronavirus vaccine: safety and immunogenicity evaluation

A candidate modified-live bovine coronavirus vaccine: safety and immunogenicity evaluation

New Microbiologica 32(1): 109-113

A modified-live vaccine against the respiratory form of bovine coronavirus (BCoV) infection was developed by progressive attenuation of a respiratory strain (438/06-TN). The vaccine was found to be safe as four colostrum-deprived newborn calves remained healthy after oronasal administration of ten doses of the vaccine. The immunogenicity of the vaccine was assessed by intramuscular injection of one vaccine dose to 30 BCoV-antibody negative 2-3-month-old calves. At 30 days post-vaccination, all vaccinated calves displayed high antibody titres against BCoV. Sequence analysis of the S gene of wild-type and cell-adapted 438/06-TN strain detected 10 nucleotide changes, 9 of which were non-synonymous.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 051083815

Download citation: RISBibTeXText

PMID: 19382676

Related references

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. Plos one 5(1): E8816, 2010

Evaluation of the immunogenicity, latency, and safety of a new genetically engineered bovine herpes virus vaccine candidate. 1999

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. Plos one 5(11): E13983, 2010

Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). Journal of Infectious Diseases 213(6): 922-929, 2016

Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine 32(Suppl. 1): A117-A123, 2014

Safety of a new modified live virus vaccine against canine coronavirus. Canine Practice 25(1): 16-19, 2000

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 26(26): 3291-3296, 2008

Safety and efficacy of a modified-live canine coronavirus vaccine in dogs. Veterinary Microbiology 99(1): 43-49, 2004

Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi. Vaccine 26(7): 998, 2008

Evaluation of the safety, immunogenicity and virus shedding of an intranasal live attenuated Bovine parainfluenza virus type 3 vaccine in infants. Pediatric Research 45(4 Part 2): 161A, 1999

Phase I study of the safety and immunogenicity of rDEN4 Delta 30-200,201 a live attenuated virus vaccine candidate for dengue serotype 4. 2007

Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine. Australian Veterinary Journal 92(11): 450-457, 2014

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infection and Immunity 64(11): 4542-4548, 1996

Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. Journal of Infectious Diseases 192(4): 573-579, 2005

Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate. Vaccine 11(5): 587-590, 1993